Newcomer Lee Nisley 4

What Happened

• Lee Nisley, a director of Coherus Oncology, received two equity awards on 2026-06-05: 30,000 restricted stock units (RSUs) and a 60,000-share derivative award (options). Both grants were reported at $0 acquisition price (typical for compensation awards reported on Form 4). These are grants — not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-05; Form 4 filed 2026-06-09 (filed within the two-business-day reporting window).
• Awards and amounts: 30,000 RSUs (F1) and 60,000 derivative/option shares (F2), reported at $0.
• Vesting/exercise schedule: RSUs vest 100% on the one-year anniversary of June 3, 2026 (i.e., June 3, 2027). The 60,000 option shares become vested and exercisable 100% on June 3, 2027 (per footnotes).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: F1 explains RSUs convert to one share per RSU upon vesting; F2 states the underlying option shares vest/become exercisable on June 3, 2027.

Context

• RSUs convert to actual shares only upon vesting; until then they are a promise of future shares tied to continued service. The derivative award (options) becomes exercisable on the stated vesting date — this is a grant of potential future stock, not an immediate purchase or sale.
• These types of awards are common as director compensation and do not, by themselves, indicate an insider buying or selling stock.